Royalty Pharma plc (Class A) (RPRX) exhibits 45.0% gross margins and 7.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 27.8x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 65.6% operating margin and 7.0% ROIC, outpacing sector cost of capital.
ROIC: 7.0% // GM: 45.0%YoY revenue trajectory of +5.1% paired with 6.29% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.1% // FCF YLD: 6.29%Altman Z-Score of 2.90 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.90 // F-SCORE: 8/9Trading at 49.2x trailing P/E (45.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 49.2x // EV/EBITDA: 27.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $67.18 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 32.4% net margins.
NET MARGIN: 32.4% // D/E: 0.88x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for RPRX & activate live FRED threshold breach alerts.